TorreyPines Therapeutics Initiates Phase II Study Of Muscarinic Agonist NGX267 For Treatment Of Xerostomia
Apr 2nd 2008Drug InformationEndocrinology
TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced it has initiated a Phase II study of NGX267, a muscarinic agonist in development for xerostomia, or dry mouth, secondary to Sjogren’s syndrome. The company is conducting a randomized, double-blind, placebo-controlled, cross-over study with a Latin square design to evaluate the safety, tolerability and efficacy of this once-a-day compound.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
